ASK REDCHAT ANYTHING ABOUT CYTOMX THERAPEUTICS INC.
CytomX Therapeutics Inc. (NASDAQ: CTMX)
Listen to this Section
$3.04
-0.1450
(
-4.56% )
1.8M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| BMS-986288 (Anti-CTLA-4 non-fucosylated Probody)DetailsColorectal cancer , Solid tumor/s |
Phase 2 |
| CX-801 + KEYTRUDADetailsCancer, Solid tumor/s, Melanoma, Renal cell carcinoma, Head and neck squamous cell carcinoma |
Phase 1a |
| CX-2051 (EpCAM expression)DetailsCancer, Solid tumor/s |
Phase 1a |
| CX-904 (EGFRxCD3)DetailsCancer, Solid tumor/s |
Phase 1b |
| CX-2029 (PDC directed against CD71)DetailsNon-small cell lung carcinoma, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s |
Failed |
| BMS-986249 (CTLA-4-directed Probody therapeutic)DetailsCancer, Melanoma |
Failed |
| Pacmilimab (CX-072) + CX-2009 (PD-L1 Targeting Probody Immunotherapy + CD166 PDC)DetailsCancer, Triple-negative breast cancer |
Failed |
| Praluzatamab ravtansine (CX-2009) (anti-CD166)DetailsCancer, HER2-expressing cancers, Breast cancer |
Failed |
Market Data
|
| Open |
$3.04 |
| Previous Close |
$3.18 |
| Volume |
1.8M |
| Market Cap |
$701.00M |
| Day Range |
$3.03 - $3.23 |
| 52 Week Range |
$1.72 - $8.21 |
| Shares Outstanding |
217.70M |
| Change % |
-4.56% |
| Net Change |
▼ -0.1450 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2015 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-937,984.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-01-19 |
Sale |
-26250.00 |
Chu Yu-Waye |
| 2023-12-22 |
Sale |
-1990.00 |
Ogden Christopher |
| 2023-12-22 |
Sale |
-4077.00 |
ROWLAND LLOYD A |
| 2023-12-22 |
Sale |
-4077.00 |
Landau Jeffrey B |
| 2023-12-22 |
Sale |
-4077.00 |
BELVIN MARCIA |
| 2023-12-22 |
Sale |
-13551.00 |
McCarthy Sean A. |
| 2023-12-19 |
Sale |
-11250.00 |
ROWLAND LLOYD A |
| 2023-12-19 |
Sale |
-11250.00 |
BELVIN MARCIA |
| 2023-12-19 |
Sale |
-6875.00 |
Ogden Christopher |
| 2023-12-19 |
Sale |
-37500.00 |
McCarthy Sean A. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
1 |
Nov 14, 2025 |
| schedule |
Other |
1 |
Nov 14, 2025 |
| schedule |
Other |
2 |
Nov 14, 2025 |
| 4 |
Insider transactions |
1 |
Nov 10, 2025 |
| 10-q |
Quarterly Reports |
71 |
Nov 06, 2025 |
| 8-k |
8K-related |
11 |
Nov 06, 2025 |
| 4 |
Insider transactions |
1 |
Oct 29, 2025 |
| 3 |
Insider transactions |
2 |
Oct 29, 2025 |
| 4 |
Insider transactions |
1 |
Sep 30, 2025 |
| 4 |
Insider transactions |
1 |
Sep 30, 2025 |